Proptosis clinical trials at UCLA

1 in progress, 0 open to eligible people

Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sorry, in progress, not accepting new patients
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Los Angeles, California and other locations

Last updated: May 29, 2024

Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)